Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Eli Lilly & Co. is expanding its cancer drug pipeline by buying back a compound it sold to TVM Capital Life Science in 2016. TVM founded AurKa Pharma to develop the compound, AK-01, and AurKa is now testing it in several solid tumors in Phase I clinical trials. Lilly will pay $110 million for AurKa plus up to $465 million in milestone payments. AK-01 inhibits a protein called Aurora kinase A, which plays a role in controlling cell division. Too much of the protein can promote cancer.
This article has been sent to the following recipient: